Histologic re‑evaluation of a population‑based series of renal cell carcinomas from The Netherlands Cohort Study according to the 2022 ISUP/WHO classification.

ISUP grading LVI TNM 8th edition necrosis newly described RCC entities rhabdoid and sarcomatoid features

Journal

Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
May 2023
Historique:
received: 13 10 2022
accepted: 04 01 2023
medline: 11 4 2023
entrez: 10 4 2023
pubmed: 11 4 2023
Statut: epublish

Résumé

The aim of the present study was to re-evaluate 457 renal cell carcinoma (RCC) cases from the Netherlands Cohort Study on Diet and Cancer (NLCS), a large population-based cohort, according to the new 2022 ISUP, Genitourinary Pathology Society and World Health Organisation (WHO) classifications to assess whether newly recognized subtypes of RCC could be found among these cases. These cases were initially evaluated according to the 2004 WHO classification, the Fuhrman grading system and the 3rd version of the Tumor-Node-Metastasis (TNM). Data on tumor size, laterality and date of diagnosis, among other clinicopathological characteristics, were obtained through record linkage with the Netherlands Cancer Registry and the Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief. Digital slides from the NLCS were reviewed by two urogenital pathologists according to the new ISUP grading and the 2022 WHO classification (5th edition). Immunohistochemistry staining for carbonic anhydrase IX was performed on cases with ambiguous morphology. A total of 373 cases of clear cell RCC (ccRCC), 61 cases of papillary RCC (pRCC), 13 cases of chromophobe RCC, 3 cases of collecting duct carcinoma and 4 cases of oncocytoma were identified. The subtyping showed no discrepancy with the previous diagnoses. A comparison of the WHO/ISUP grading to the original Fuhrman grading showed a similar grading in 245 (56.5%) cases of the total ccRCC and pRCC cases. The staging according to the novel TNM classification 8th edition showed a restaging in 286 cases (65.5%). Lymphovascular (microvascular) invasion (LVI) and tumor necrosis (TN) were present in 14.4% and 33.5% of the total number of cases, respectively. Furthermore, the presence of sarcomatoid differentiation in 5.1% and rhabdoid differentiation in 4.2% of the cases was observed. In conclusion, none of the newly accepted and emerging/provisional RCC entities were identified in the NLCS cases, which could be attributed to the high mean age (71.4 years) at diagnosis of the patients included in the present study. A restaging of the NLCS cases using the TNM 8th edition and regrading using ISUP grading was performed, which showed that it is possible to report on newer features, such as sarcomatoid differentiation and LVI, even in an old sample collection.

Identifiants

pubmed: 37033104
doi: 10.3892/ol.2023.13760
pii: OL-25-5-13760
pmc: PMC10080194
doi:

Types de publication

Journal Article

Langues

eng

Pagination

174

Informations de copyright

Copyright: © Odeh et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Am J Surg Pathol. 2021 Apr 1;45(4):450-462
pubmed: 33239504
Eur Urol. 2021 Feb;79(2):225-231
pubmed: 33172723
Am J Surg Pathol. 2016 Sep;40(9):1224-31
pubmed: 27428737
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Urol Oncol. 2016 May;34(5):238.e1-7
pubmed: 26723226
Int J Mol Sci. 2017 Oct 20;18(10):
pubmed: 29053609
Histopathology. 2018 Mar;72(4):588-600
pubmed: 28898443
Urology. 2014 May;83(5):969-74
pubmed: 24661331
World J Urol. 2018 Dec;36(12):1913-1926
pubmed: 30123932
Am J Surg Pathol. 2006 Sep;30(9):1091-6
pubmed: 16931953
Eur Urol. 2004 Sep;46(3):331-5
pubmed: 15306103
Hum Pathol. 2014 Jul;45(7):1437-44
pubmed: 24784922
Am J Surg Pathol. 2013 Oct;37(10):1469-89
pubmed: 24025519
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
J Urol. 1997 Jul;158(1):45-9
pubmed: 9186320
BJU Int. 2009 Aug;104(4):461-9
pubmed: 19338563
J Kidney Cancer VHL. 2014 Jul 20;1(3):26-39
pubmed: 28326247
Int J Epidemiol. 2017 Apr 1;46(2):622-631
pubmed: 27789672
Nat Commun. 2016 Oct 07;7:13131
pubmed: 27713405
BMC Cancer. 2018 Sep 3;18(1):870
pubmed: 30176824
J Clin Epidemiol. 1990;43(3):285-95
pubmed: 2313318
Biomed Res Int. 2015;2015:476508
pubmed: 26448938
Clin Cancer Res. 2017 Apr 15;23(8):2006-2018
pubmed: 27756787
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Eur Urol. 2006 May;49(5):798-805
pubmed: 16442207
J Clin Pathol. 2019 Sep;72(9):573-578
pubmed: 31300532
Hum Pathol. 2018 Apr;74:25-31
pubmed: 29133143
Cancer Biomark. 2010;9(1-6):461-73
pubmed: 22112490
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Radiographics. 2006 Nov-Dec;26(6):1795-806; discussion 1806-10
pubmed: 17102051
Kidney Cancer. 2019 Nov 01;3(3):151-161
pubmed: 31867475
Cancer Cytopathol. 2019 Feb;127(2):79-97
pubmed: 30690877
Springerplus. 2013 Aug 10;2:378
pubmed: 24010036
Annu Rev Pathol. 2015;10:263-89
pubmed: 25387056
Urol Oncol. 2014 Jan;32(1):30.e23-8
pubmed: 23428539
Pathology. 2018 Jan;50(1):24-36
pubmed: 29132724
Am J Surg Pathol. 1982 Oct;6(7):655-63
pubmed: 7180965
Pathologe. 2016 Jul;37(4):355-60
pubmed: 27271258
Hum Pathol. 2014 Apr;45(4):735-44
pubmed: 24499686
Oncologist. 2012;17(1):46-54
pubmed: 22234634
J Clin Pathol. 2005 Jan;58(1):39-43
pubmed: 15623480
Cent European J Urol. 2018;71(4):386-390
pubmed: 30680230
Ann Transl Med. 2019 Mar;7(Suppl 1):S18
pubmed: 31032299
Am J Surg Pathol. 2013 Oct;37(10):1490-504
pubmed: 24025520
J Urol. 2010 Mar;183(3):909-14
pubmed: 20083280
Eur Urol. 2018 Apr;73(4):560-569
pubmed: 29325693
Int J Urol. 2012 Oct;19(10):894-900
pubmed: 22715810
Clin Epigenetics. 2021 May 4;13(1):103
pubmed: 33947447
BMC Cancer. 2005 Jun 02;5:57
pubmed: 15932632
Eur Urol. 2000 Dec;38(6):728-33
pubmed: 11111192
Arch Pathol Lab Med. 2012 Apr;136(4):391-9
pubmed: 22458901
Transl Androl Urol. 2020 Dec;9(6):2665-2674
pubmed: 33457238
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Histopathology. 2019 Jan;74(1):4-17
pubmed: 30565310
Mod Pathol. 2021 Jun;34(6):1167-1184
pubmed: 33526874
F1000Res. 2018 Mar 12;7:307
pubmed: 29568504
Rontgenblatter. 1987 Jun;40(6):200
pubmed: 3616430
Viruses. 2020 Dec 08;12(12):
pubmed: 33302606
Histopathology. 2019 Jan;74(1):31-59
pubmed: 30565301
Mod Pathol. 2009 Jun;22 Suppl 2:S24-36
pubmed: 19494851

Auteurs

Selena Odeh (S)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Iryna V Samarska (IV)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Andres Matoso (A)

Department of Pathology, Johns Hopkins University, Baltimore, MD 21218, USA.
Department of Urology, Johns Hopkins University, Baltimore, MD 21218, USA.
Department of Oncology, Johns Hopkins University, Baltimore, MD 21218, USA.

Jeroen A A Van De Pol (JAA)

Department of Epidemiology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Marcella M L L Baldewijns (MMLL)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.
Department of Histopathology, University of Leuven, 3000 Leuven, Belgium.

Christina A Hulsbergen-Van De Kaa (CA)

Department of Pathology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Laboratory of Pathology East Netherlands (LABPON), 7550 AM Hengelo, The Netherlands.

Jaleesa Van Der Meer (J)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Guido Roemen (G)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Erik Geelkens (E)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Manon Van Engeland (M)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Axel Zur Hausen (A)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Leo J Schouten (LJ)

Department of Epidemiology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Kim M Smits (KM)

Department of Pathology, School for Oncology and Reproduction (GROW), Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Classifications MeSH